- Home
- VIGL vs GRWG Comparison
VIGL vs GRWG Comparison
Compare VIGL & GRWG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- GRWG
- Stock Information
- Founded
- VIGL 2020
- GRWG 2008
- Country
- VIGL United States
- GRWG United States
- Employees
- VIGL N/A
- GRWG N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- GRWG RETAIL: Building Materials
- Sector
- VIGL Health Care
- GRWG Consumer Discretionary
- Exchange
- VIGL Nasdaq
- GRWG Nasdaq
- Market Cap
- VIGL 89.3M
- GRWG 82.3M
- IPO Year
- VIGL 2022
- GRWG N/A
- Fundamental
- Price
- VIGL $2.11
- GRWG $0.97
- Analyst Decision
- VIGL Strong Buy
- GRWG Hold
- Analyst Count
- VIGL 5
- GRWG 5
- Target Price
- VIGL $21.00
- GRWG $2.75
- AVG Volume (30 Days)
- VIGL 227.2K
- GRWG 742.0K
- Earning Date
- VIGL 03-13-2025
- GRWG 03-13-2025
- Dividend Yield
- VIGL N/A
- GRWG N/A
- EPS Growth
- VIGL N/A
- GRWG N/A
- EPS
- VIGL N/A
- GRWG N/A
- Revenue
- VIGL N/A
- GRWG $200,882,000.00
- Revenue This Year
- VIGL N/A
- GRWG N/A
- Revenue Next Year
- VIGL N/A
- GRWG N/A
- P/E Ratio
- VIGL N/A
- GRWG N/A
- Revenue Growth
- VIGL N/A
- GRWG N/A
- 52 Week Low
- VIGL $1.49
- GRWG $0.96
- 52 Week High
- VIGL $6.06
- GRWG $3.38
- Technical
- Relative Strength Index (RSI)
- VIGL 38.32
- GRWG 25.37
- Support Level
- VIGL $2.15
- GRWG $0.97
- Resistance Level
- VIGL $2.55
- GRWG $1.18
- Average True Range (ATR)
- VIGL 0.23
- GRWG 0.08
- MACD
- VIGL -0.05
- GRWG -0.01
- Stochastic Oscillator
- VIGL 4.72
- GRWG 2.94
Stock Price Comparison Chart: VIGL vs GRWG
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About GRWG GrowGeneration Corp.
GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, advanced indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.